Mycobacterium tuberculosis (Mtb), the principal etiological agent of tuberculosis (TB), infects over one-third of humanity and is now the leading cause of infectious disease mortality by a single pathogen. Mtb requires iron for survival and obtains this essential micronutrient in vivo through the synthesis, secretion, and re-uptake of siderophores or small-molecule iron chelators known as the mycobactins. In preliminary studies using a genetic approach, we have shown mycobactin biosynthesis is essential for Mtb infection in mice. We have synthesized a selective nanomolar inhibitor of mycobactin biosynthesis termed Sal-AMS that targets the enzyme MbtA, responsible for the first and committed biosynthetic step of the mycobactins. The objectives of this application are: 1) to dramatically improve upon the in vivo efficacy of our lead compound Sal-AMS through the optimization of its pharmacokinetic parameters and potency, 2) to more deeply illuminate the mechanism of action and resistance in Mtb, 3) to determine the safety profile and potential drug-drug interactions, and 4) to identify interactive effects with other TB drugs (i.e. synergy). We will accomplish the overall objectives of this application by pursuing three specific aims.
In aim 1, we will carry out an iterative structure-based medicinal chemistry program to concurrently optimize pharmacokinetic (PK) parameters and whole-cell activity using a combination of approaches including fluorination, structural simplification of the nucleoside, and introduction of conformation constraints into the inhibitor.
In aim 2, we will perform biochemical and cellular studies to evaluate enzyme inhibition, target engagement, cellular accumulation, and whole-cell activity against Mtb as well as drug-resistant strains. Generation of resistant strains followed by whole-genome sequencing will be used to characterize potential resistance mechanisms and determine the resistance frequency. Finally, combination studies with various first and second-line TB drugs will be undertaken to assess potential for synergy.
In aim 3, the siderophore inhibitors will be assessed in vivo to determine their complete pharmacokinetic parameters with a goal to improve on the volume of distribution (Vd), intrinsic clearance (CL), and bioavailability (F). We will conduct chronic toxicity studies and evaluate compounds against a panel of assays (hERG, CYP inhibition, kinase panel) to ensure safety and selectivity. In vivo efficacy studies will be done using a murine model of TB infection.
Tuberculosis (TB) caused by the slow growing bacillus Mycobacterium tuberculosis (Mtb) is the leading cause of infectious disease mortality in the world by a single pathogen. M. tuberculosis and other atypical mycobacteria are also classified as opportunistic infections of AIDS patients. The proposed research is expected to lead to a new class of antitubercular agents that operate by a unique mechanism of action through disruption of iron acquisition.
